• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
NF-kB Pathway
You are here: Product Lines > Signal Transduction > NF-kB Pathway
 
Toolbar - View Selection
 
 Items 100-120 of 126 Page 6 of 7 Select Page: << 1 2 3 4 5 6 7  >>  
ALX-840-609 Revised 03-May-07
Positive Control (Cell Lysate) for Antibodies to RIG-I (human)
Add to Clipboard
SYNONYMS Positive Control (Cell Lysate) for Antibodies to RIG-1 (human)
Positive Control (Cell Lysate) for Antibodies to Retinoic Acid-inducible Gene 1 (human)
Positive Control (Cell Lysate) for Antibodies to DEAD-box Protein 58 (human)
Positive Control (Cell Lysate) for Antibodies to Probable ATP-dependent RNA Helicase DDX58 (human)
PRODUCT LINE Immunology
PRODUCT CATEGORY Positive Controls (Cell Lysates & Extracts)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-840-609-R100   100 µl 70.00 USD Add To Cart
Product Specification
SOURCE/HOST: Whole cell lysate of HEK293T cells transfected with an expression plasmid for human RIG-I (aa 1-925).
QUANTITY: 100µl corresponding to 2x105 cells.
PURITY: ≥95%
FORMULATION: Liquid. In 5x sample buffer (312.5mM TRIS, pH 6.8, containing 10% SDS, 6% glycerol, 0.075% bromophenol blue, 10% β-mercaptoethanol and 10mM DTT).
APPLICATION: Positive control in Western blot for MAb to RIG-I (human) (Alme-1)
(ALX-804-849) and PAb to RIG-I (human) (AT111) (Prod. No. ALX-210-932). Add 13µl sterile water and 2µl DTT (100mM) to 5µl of cell lysate.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
General Information
MANUFACTURER Manufactured by Apotech Corporation.
Related Products
Further Categories Containing This Product:
NF-kB Pathway Other Products • Caspase Recruitment Domain [CARD] Proteins/Related Products
 
 
ALX-270-458 Revised 15-Jan-08
PPM-18
Add to Clipboard
SYNONYMS 2-Benzoylamino-1,4-naphthoquinone
PRODUCT LINE Nitric Oxide Pathway
PRODUCT CATEGORY NOS Inhibitors (NOS Induction & Enzyme Activity)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-458-M010   10 mg 140.00 USD Add To Cart
Product Specification
FORMULA: C17H11NO3
MW: 277.3
CAS NUMBER: 65240-86-0
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow to orange solid.
SOLUBILITY: Soluble in DMSO or acetonitrile.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY:

Stable for at least 3 years after receipt when stored at -20°C.
HANDLING: Packaged under inert gas. Protect from light. After reconstitution, prepare aliquots and store at -20°C.

Product Description
Cell permeable, anti-inflammatory agent that inhibits expression of iNOS (NOS II) (IC50~5mM). Blocks activation of NF-κB in vitro and in vivo. Does not directly affect enzymatic activities of iNOS (NOS II) or eNOS (NOS III).
Product Specific Literature References
Synthesis and antiplatelet, antiinflammatory and antiallergic activities of 2,3-disubstituted 1,4-naphthoquinones: J.C. Lien, et al.; Chem. Pharm. Bull. (Tokyo) 44, 1181 (1996) Abstract
Inhibition of nitric oxide synthase expression by PPM-18, a novel anti-inflammatory agent, in vitro and in vivo: S.M. Yu, et al.; Biochem. J. 328, 363 (1997) Abstract; Full Text
Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding: M.E. Davis, et al.; J. Biol. Chem. 279, 163 (2004) Abstract; Full Text
Further Categories Containing This Product:
NF-kB Pathway Modulators • Anti-inflammatory Agents Other Products
 
 
ALX-400-002 Revised 15-May-08
Pyrrolidinedithiocarbamic acid . ammonium salt
Add to Clipboard
SYNONYMS Ammoniumpyrrolidinedithiocarbamate
Ammoniumtetramethylenedithiocarbamate
PRODUCT LINE Signal Transduction
PRODUCT CATEGORY NF-kB Pathway Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-400-002-G005   5 g 29.00 USD Add To Cart
ALX-400-002-G025   25 g 55.00 USD Add To Cart
Product Specification
FORMULA: C5H8NS2 . NH4
MW: 146.3 . 18.0
CAS NUMBER: 5108-96-3
PURITY: ≥98%
APPEARANCE: White to-off white solid.
SOLUBILITY: Soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HAZARD: IRRITANT.

Product Description
Inhibitor of NF-κB activation (induced by either PMA or TNF-α) in various cell types.
Product Specific Literature References
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells: R. Schreck, et al.; J. Exp. Med. 175, 1181 (1992) Abstract
Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes: H.W. Ziegler-Heitbrock, et al.; J. Immunol. 151, 6986 (1993) Abstract
Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages: M.P. Sherman, et al.; BBRC 191, 1301 (1993) Abstract
Pyrrolidine dithiocarbamate differentially affects interleukin 1 beta- and cAMP-induced nitric oxide synthase expression in rat renal mesangial cells: W. Eberhardt, et al.; BBRC 200, 163 (1994) Abstract
In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation: T.S. Blackwell, et al.; Immunol. 157, 1630 (1996) Abstract
In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock: S.F. Liu, et al.; J. Immunol. 159, 3976 (1997) Abstract
Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kappaB activation: C.H. Kim, et al.; FEBS Lett. 449, 28 (1999) Abstract
Dual activity of pyrrolidine dithiocarbamate on kappa B-dependent gene expression in U937 cells: I. Regulation by the phorbol ester TPA: K. Watanabe, et al.; Cell Signal 11, 479 (1999) Abstract
Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes: S.F. Liu, et al.; Circulation 100, 1330 (1999) Abstract
Dual activity of pyrrolidine dithiocarbamate on kappaB-dependent gene expression in U937 cells: II. Regulation by tumour necrosis factor- alpha: K. Watanabe, et al.; Cell Signal 11, 371 (1999) Abstract
Pyrrolidine dithiocarbamate inhibits TNF-alpha-dependent activation of NF-kappaB by increasing intracellular copper level in human aortic smooth muscle cells: A. Iseki, et al.; Biochem Biophys Res Commun 276, 88 (2000) Abstract
 
 
ALX-420-038 Revised 09-May-07
R-848
Add to Clipboard
SYNONYMS 4-Amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
S 28463
Resiquimod
PRODUCT LINE Immunology
PRODUCT CATEGORY Immunomodulators Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-420-038-M005   5 mg 50.00 USD Add To Cart
ALX-420-038-M025   25 mg 200.00 USD Add To Cart
Product Specification
FORMULA: C17H22N4O2
MW: 314.4
CAS NUMBER: 144875-48-9
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO, 100% methanol or 5% methanol in dichloromethane. Poorly soluble in acetonitrile or ethyl acetate.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Selective ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Potent antitumor and antiviral compound. Stimulates antibody secretion, cytokine production, protection from apoptosis and CD80 upregulation.
Product Specific Literature References
The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001) Abstract
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) Abstract
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002) Abstract
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses: J.J. Wu, et al.; Antiviral Res. 64, 79 (2004) Abstract
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005) Abstract
Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells: G. Caron, et al.; J. Immunol. 175, 1551 (2005) Abstract; Full Text
Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848): M.J. McCluskie, et al.; Antiviral Res. 69, 77 (2006) Abstract
Further Categories Containing This Product:
TLR Agonists Other Products • CD40 & CD40L [CD154]/Related Products • Inflammasome
 
 
ALX-380-092 Revised 03-Jul-08
Radicicol
Add to Clipboard
SYNONYMS Monorden
1aS-(1aR*,2Z,4E,14*,15aR*)]-8-Chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Antifungal
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-092-M001   1 mg 75.00 USD Add To Cart
ALX-380-092-M005   5 mg 295.00 USD Add To Cart
Product Specification
FORMULA: C18H17ClO6
MW: 364.8
CAS NUMBER: 12772-57-5
MERCK INDEX: 14: 6253
RTECS: RR1105000
SOURCE/HOST: Isolated from Humicola fuscoatra.
PURITY: ≥98% (HPLC)
APPEARANCE: White to light yellow powder.
SOLUBILITY: Soluble in DMSO, methanol or acetone.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: MAY BE CARCINOGENIC. HARMFUL.

Product Description
Antifungal macrocyclic lactone antibiotic with antimalarial activity. Potent inhibitor of HSP90. Binds more strongly to HSP90 (nanomolar affinity) than to Grp94. Also binds to yeast HSP90, E. coli HtpG and TRAP-1. Non-competitive inhibitor of ATP citrate lyase. Anti-angiogenic. Specifically inhibits the interaction between HIF-1α/Arnt heterodimer and the hypoxia-responsive element (HRE), reducing VEGF expression. Protein tyrosine kinase inhibitor, e.g. p60v-src (IC50=0.27nM). Inhibitor of cyclooxygenase-2 (COX-2) expression (IC50=27nM) without affecting COX-1 expression in LPS-stimulated macrophages. Induces the differentiation of HL-60 cells into macrophages, blocking cell cycle at G1 and G2. Suppressor of NIH 3T3 cell transformation by diverse oncogenes such as mos, ras and src in part by blocking the key signal transduction intermediates such as MAP kinase and GAP-associated p62. Inhibitor of AP-1-, NF-κB- and serum response factor (SRF)-mediated transcription (e.g. expression of iNOS). Represses the transcriptional function of the estrogen receptor. Inhibits archeal growth and DNA topoisomerase VI (a Topo IIB family topoisomerase). Blocks replication of negative-strand RNA viruses.
Product Specific Literature References
Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol: H.J. Kwon, et al.; Cancer Res. 52, 6926 (1992) Abstract
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis: T. Oikawa, et al.; Eur. J. Pharmacol. 241, 221 (1993) Abstract
Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis: P. Chanmugam, et al.; J. Biol. Chem. 270, 5418 (1995) Abstract; Full Text
Suppression of RAS and MOS transformation by radicicol: J.F. Zhao, et al.; Oncogene 11, 161 (1995) Abstract
Induction of differentiation of HL-60 cells by the anti-fungal antibiotic, radicicol: Y. Shimada, et al.; J. Antibiot. 48, 824 (1995) Abstract
Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from mitosis of Src-transformed cells: I. Pillay, et al.; Cell Growth Differ. 7, 1487 (1996) Abstract
Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway: S. Soga, et al.; J. Biol. Chem. 273, 822 (1998) Abstract; Full Text
Antimalarial activity of radicicol, heptelidic acid and other fungal metabolites: Y. Tanaka, et al.; J. Antibiot. 51, 153 (1998) Abstract
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol: S.V. Sharma, et al.; Oncogene 16, 2369 (1998) Abstract
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin: S.M. Roe, et al.; J. Med. Chem. 42, 260 (1999) Abstract
T.W. Schulte, et al.; Mol. Endocrinol. 13, 1435 (1999) Abstract; Full Text
Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages: Y.J. Jeon, et al.; J. Pharmacol. Exp. Ther. 294, 548 (2000) Abstract; Full Text
Radicicol binds and inhibits mammalian ATP citrate lyase: S.W. Ki, et al.; J. Biol. Chem. 275, 39231 (2000) Abstract; Full Text
Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade: P.N. Kim, et al.; Cell Growth Differ. 12, 543 (2001) Abstract; Full Text
Radicicol-sensitive peptide binding to the N-terminal portion of GRP94: S. Vogen, et al.; J. Biol. Chem. 277, 40742 (2002) Abstract; Full Text
Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol: E. Hur, et al.; Mol. Pharmacol. 62, 975 (2002) Abstract; Full Text
Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90: M.O. Lee, et al.; Mol. Cell Endocrinol. 188, 47 (2002) Abstract
Development of radicicol analogues: S. Soga, et al.; Curr. Cancer Drug Targets 3, 359 (2003) Abstract
Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor: K. Harashima, et al.; Int. J. Radiat. Biol. 81, 63 (2005) Abstract
Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol: D. Gadelle, et al.; Nucleic Acid Res. 33, 2310 (2005) Abstract
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site: M.K. Hadden, et al.; Curr. Top. Med. Chem. 6, 1173 (2006), Review Abstract
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?: C.R. Barker, et al.; Int. J. Cancer 118, 2685 (2006) Abstract
Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol: K.D. Corbett & J.M. Berger; Nucleic Acids Res. 34, 4269 (2006) Abstract
Chemistry and biology of resorcylic acid lactones: N. Winssinger & S. Barluenga; Chem. Commun. (Camb.) 22 (2007) Abstract
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses: J.H. Connor, et al.; Virology 362, 109 (2007) Abstract
Further Categories Containing This Product:
NF-kB Pathway Inhibitors • Cell Cycle Blockers & Inhibitors/Related Products • Tyrosine Kinase Inhibitors • Antibiotics - Nitric Oxide Pathway Modulators • Antitumor Agents (Hormone-related) • Estrogen & Estrogen Receptors/Related Products • Malaria/Related Products • Antibiotics - Antimalarial • Antibiotics - Protein Kinase Inhibitors • Antibiotics - NF-kB Inhibitors • Antibiotics for Angiogenesis Research • Antibiotics for Cell Cycle Research • HSP90/HtpG/Related Products • Antibiotics - Topoisomerase Inhibitors • RNA Polymerases/Related Products
 
 
ALX-201-410 Revised 13-Feb-08
Ribosomal Protein S3 (human) (recombinant)
Add to Clipboard
PRODUCT LINE Protein Synthesis, Modification & Degradation
PRODUCT CATEGORY Ribosomal Proteins/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-410-C010   10 µg 330.00 USD Add To Cart
ALX-201-410-C050   50 µg 740.00 USD Add To Cart
Product Specification
SOURCE/HOST: Produced in E. coli. The mature peptide of human ribosomal protein S3 (aa 1-243) is fused at the N-terminus to a tag.
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. 0.2µm-filtered solution in 25mM TRIS-HCl, pH 8.5, containing 1mM DTT.
ENDOTOXIN CONTENT: <1EU/µg protein (LAL-test).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Working aliquots are stable for up to 3 months when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation: T.S. Kim, et al.; Mol. Biol. Cell 174, 824 (2006) Abstract; Full Text
Reduction of invasion in human fibrosarcoma cells by ribosomal protein S3 in conjunction with Nm23-H1 and ERK: S.H. Kim & J. Kim; Biochim. Biophys. Acta 1763, 823 (2006) Abstract
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation: F. Wan, et al.; Cell 131, 927 (2007) Abstract
General Information
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link P23396: Ribosomal Protein S3 (human)
MANUFACTURER Manufactured by AdipoGen, Inc.
Further Categories Containing This Product:
Co-Chaperones & HSP-interacting Proteins/Related Products • Recombinant Proteins/Fusion Proteins • DNA Endonucleases/Related Products • NF-kB Pathway Other Products • MAPK Pathway Other Products
 
 
ALX-201-408 Revised 27-Mar-08
Ribosomal Protein S3 (human) (recombinant) (His)
Add to Clipboard
SYNONYMS RPS3 (human) (recombinant) (His)
40S Ribosomal Protein S3
IMR-90 Ribosomal Protein S3
PRODUCT LINE Protein Synthesis, Modification & Degradation
PRODUCT CATEGORY Ribosomal Proteins/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-201-408-C010   10 µg 330.00 USD Add To Cart
ALX-201-408-C050   50 µg 740.00 USD Add To Cart
Product Specification
SOURCE/HOST: Produced in E. coli. Mature peptide of human ribosomal protein S3 (aa 1-243) is fused at the C-terminus to a His-tag.
PURITY: ≥90% (SDS-PAGE)
FORMULATION: Liquid. 0.2µm-filtered solution in 25mM TRIS-HCl, pH 8.5, containing 1mM DTT.
ENDOTOXIN CONTENT: <1EU/µg protein (LAL-test).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Working aliquots are stable for up to 3 months when stored at -20°C.
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation: T.S. Kim, et al.; Mol. Biol. Cell 17, 824 (2006) Abstract; Full Text
Reduction of invasion in human fibrosarcoma cells by ribosomal protein S3 in conjunction with Nm23-H1 and ERK: S.H. Kim & J. Kim; Biochim. Biophys. Acta 1763, 823 (2006) Abstract
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation: F. Wan, et al.; Cell 131, 927 (2007) Abstract
General Information
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link P23396: Ribosomal Protein S3 (human)
MANUFACTURER Manufactured by AdipoGen, Inc.
Related Products
Further Categories Containing This Product:
Co-Chaperones & HSP-interacting Proteins/Related Products • Recombinant Proteins/Fusion Proteins • DNA Endonucleases/Related Products • NF-kB Pathway Other Products • MAPK Pathway Other Products
 
 
APO-54N-038 Revised 27-May-08 New product
RIG-I (human) Detection Set (IntraCellular) [For ELISA Application]
Add to Clipboard
SYNONYMS Retinoic Acid-inducible Gene 1 (human) Detection Set (IntraCellular) [For ELISA Application]
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY RNA Helicases/Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
APO-54N-038-KI01   1 Set 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SENSITIVITY: 0.4ng/ml (range 0 to 32ng/ml).
QUANTITY: For 5x96 wells.
KIT/SET CONTAINS: 1 vial Standard (lyophilized) (STD).
1 vial Coating Antibody (COAT).
1 vial Detection Antibody (DET).
APPLICATION: For the quantitative determination of human RIG-I in cell extracts.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
General Information
The innate immune response to viruses is initiated upon detection of viral RNA generated during the life cycle of most viruses [1]. Recognition of the viral RNA is mediated by either the two cytoplasmic RNA helicases Retinoic acid Inducible Gene-1 (RIG-I ; Ddx58) and Melanoma Differentiation Associated gene 5 (MDA5 / Helicard) [2] or by Toll-like Receptor 3 (TLR3) located to an endosomal-like compartment [3]. RIG-I and MDA5 belong to the family of RIG-I like receptor (RLR) together with the protein LGP2 whose function is still elusive [4, 5]. Upon binding to RNA, RIG-I or MDA5 binds a new mediator named Cardif, MAVS, IPS-1 or VISA [6, 7] that signals through transcription factors, such as IRF-3, IRF-7, and NF-κB leading to the activation of interferons (IFNs) and other inflammatory cytokine genes. RIG-I is activated by dsRNA and 5′-ppp RNA. RIG-I has been shown to trigger innate immune signaling pathways during infection by orthomyxoviruses, rhabdovirus, vesicular stomatitis virus, and paramyxoviruses; and possibly by the filovirus Ebola virus and by the Epstein-Barr virus [8]. Virus infection induces a rapid production of IFN-α/β that leads to expression of hundreds of interferon-stimulated genes (ISGs) whose products direct antiviral actions. RIG-I belongs to the ISG gene family and monitoring its levels using the RIG-I (human) Detection Set (IC) can be used as indicator of IFN production and virus infection.